HHHelei Hou

Helei Hou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Helei Hou has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Chuantao Zhang

    Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao

    7 shared publications
  • Dantong Sun

    Department of Medical Oncology, Peking University First Hospital, Peking University

    5 shared publications
  • Huiyun Wang

    Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao

    5 shared publications
  • Xuchen Zhang

    The Affiliated Hospital of Qingdao University

    5 shared publications
  • Ning Liu

    Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

    4 shared publications
  • Shanai Song

    Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

    4 shared publications

Latest Publications

  • Open Access

    Case Report: Dramatic response of trastuzumab rezetecan in an NSCLC patient with EGFR sensitive mutation and primary ERBB2 genetic alterations

    by Lin Zhang, Chuantao Zhang, Huiyun Wang, Qingxia Li, Yongjie Wang, Xiao Huang, Dantong Sun, Helei Hou, Lijian Zhang

    Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have provided significant clinical benefit to patients with EGFR-mutant non-small cell lung cancer (NSCLC), but multiple concurrent genetic alterations may limit their efficacy. We report a case of advanced lung adenocarcinoma harboring concurrent EGFR exon 19 deletion, ERBB2 amplification, and ERBB2 p.S310F mutation. The patient experienced disease progression after multiple lines of therapy, including osimertinib-based treatment, pemetrexed/carboplatin plus ivonescimab, and nab-paclitaxel plus Endostar. Considering that primary ERBB2 genetic alterations might contribute to the limited benefit from EGFR-TKI-based therapy, the patient subsequently received trastuzumab rezetecan monotherapy. After four cycles of treatment, the patient achieved a partial response in pulmonary lesions and a complete response in intracranial metastases. This case indicates that trastuzumab rezetecan may be a promising treatment option for EGFR-mutant NSCLC with concurrent ERBB2 genetic alterations, even after failure of multiple lines of treatment.

  • Open Access

    Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer

    by Citing Guo, Zenan Fan, Cuiyan Guo, Yaning Yang, Helei Hou, Dantong Sun

    Programmed cell death-ligand 1 (PD-L1) is best known as a membrane immune checkpoint; however, accumulating evidence indicates that PD-L1 can also localize

  • Open Access

    Chicoric acid targets PYGL to normalize glycogenolysis-driven glycolysis to suppress non-small cell lung cancer

    by Xingfa Huo, Helei Hou, Chuantao Zhang, Xueqin Duan, Hongwei Lan, Yufeng Li, Na Zhou, Xiaochun Zhang

    Chicoric acid (CA), a bioactive natural compound found in Chicory and Echinacea purpurea, exhibits antiinflammatory, antioxidant, and apoptosis-inducing pr

  • Open Access

    Predicting cardiovascular toxicity in anti-PD-1/PD-L1 therapy: a risk factor analysis and model development

    by Zhihui Yan, Juan Wang, Jianxiu Sun, Run Zhang, Jia Liu, Lihua Cao, Ming Zhang, Jiangtao Yu, Helei Hou, Wenzhong Zhang

    Purpose: This study aimed to investigate risk factors for cardiovascular toxicity following anti-PD-1/PD-L1 therapy and develop a predictive model. Methods: We retrospectively collected data from 2,665 patients with solid tumors treated with anti-PD-1/PD-L1 therapy at two-center between October 2018 and October 2023.We performed univariate and multivariate logistic regression to identify predictors of cardiovascular toxicity and developed a nomogram. Internal evaluation and internal validation were performed using receiver operating characteristic (ROC), decision curve analysis (DCA), calibration curve (CC) for internal evaluation and internal validation. Results: Univariate logistic regression identified the Systemic Inflammatory Response Index (SIRI;OR 2.26, 95% CI 1.19–4.27, p = 0.012), Eastern Cooperative Oncology Group performance status (ECOG;OR 9.67, 95% CI 3.04–30.69, p < 0.001), hypertension (OR 3.50, 95% CI 1.78–6.88, p < 0.001), diabetes (OR 2.52, 95% CI 1.13–5.66, p = 0.025), tumor metastasis (OR 0.17, 95% CI 0.08–0.39, p < 0.001), tumor stage (OR 0.40, 95% CI 0.21–0.76, p = 0.006), and sex (male vs. female)(OR 0.43, 95% CI 0.19–0.96, p = 0.040) as significant predictors. Multivariate analysis confirmed ECOG (OR 9.81, 95% CI 2.73–35.25, p < 0.001) and tumor metastasis (OR 0.26, 95% CI 0.10–0.71, p = 0.008) as independent predictors. Seven variables ( p < 0.05 in univariate analysis) were included in a nomogram, which showed good accuracy and discrimination (AUC 0.77, 95% CI 0.70–0.85). Conclusions: SIRI, ECOG, hypertension, diabetes, tumor metastasis, tumor stage, and sex were significant predictors of cardiovascular toxicity. ECOG was an independent risk factor, while tumor metastasis was an independent protective factor, after adjusting for other covariates. The nomogram showed good accuracy and discrimination, with clinical utility for predicting cardiovascular toxicity risk in patients receiving anti-PD-1/PD-L1 therapy.


  • Open Access

    Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency

    by Xiao Huang, Lin Zhang, Chuantao Zhang, Huiyun Wang, Zhuhai Shao, Ning Liu, Shanai Song, Man Jiang, Helei Hou

    Background: Immune checkpoint inhibitors (ICIs) are effective against solid tumors but can trigger immune-related adverse events (irAEs), including adrenal insufficiency (AI). Given its impact on treatment efficacy and patient quality of life, understanding the clinical characteristics and outcomes of ICI-induced AI (ICI-AI) is critical.Methods: We conducted a retrospective analysis of 46 patients diagnosed with ICI-AI at a single center (May 2019–July 2024) and reviewed clinical trials/real-world studies on ICI-AI.Results: The cohort included 22 cases of isolated adrenocorticotropic hormone deficiency (IAD), 23 of hypophysitis, and 1 of primary adrenal insufficiency (PAI). Median time to AI onset was 7.8 months (range: 1.5–27.4), with a median of 7 ICIs cycles (range: 1–21). Common symptoms were fatigue, anorexia, and nausea; comorbidities included hypothyroidism (41.3%) and hyponatremia (63%). No ACTH-deficient patients recovered during follow-up, but glucocorticoid replacement alleviated symptoms in most cases (45/46). The objective remission rate for underlying malignancies post-AI was 63%. Concurrent irAEs in other organs were rare (3 cases).Conclusion: The median time to AI onset and ICIs cycles administered are key indicators of AI development. Both IAD and hypophysitis are common secondary AI manifestations; glucocorticoid replacement enables safe ICIs continuation.


  • Open Access

    Multi-omics analysis of the dynamic role of STAR+ cells in regulating platinum-based chemotherapy responses and tumor microenvironment in serous ovarian carcinoma

    by Hongwei Lan, Weihua Yan, Xiao Huang, Jiali Cui, Helei Hou

    Background: Serous ovarian carcinoma (SOC) is the most lethal subtype of ovarian cancer, with chemoresistance to platinum-based chemotherapy remaining a major challenge in improving clinical outcomes. The role of the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), in modulating chemotherapy responses is not yet fully understood.Methods: To explore the relationship between CAF subtypes and chemotherapy sensitivity, we employed single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, spatial transcriptomics, immunohistochemistry (IHC), and immunofluorescence (IF). This multi-omics approach enabled the identification, characterization, and functional analysis of CAF subtypes in both chemotherapy-sensitive and chemotherapy-resistant SOC patients.Results: We identified steroidogenic acute regulatory protein-positive (STAR+) cells as a novel CAF subtype enriched in chemotherapy-sensitive SOC patients. STAR + cells exhibited unique transcriptional profiles and were functionally enriched in pathways related to P450 drug metabolism, lipid metabolism, and amino acid metabolism, with enhanced pathway activity observed in chemotherapy-sensitive groups. Spatial transcriptomics and IF revealed that STAR + cells were closely localized to tumor cells, suggesting potential cell-cell interactions. Further communication analysis indicated that STAR + cells may suppress WNT signaling in tumor cells, contributing to improved chemotherapy responses. Importantly, STAR expression levels, validated by IHC, were positively correlated with chemotherapy sensitivity and improved patient prognosis. Platinum-based chemotherapy was shown to increase the proportion of STAR + cells, underscoring their dynamic response to treatment.Conclusion: Our study identifies STAR + cells as a novel CAF subtype that enhances chemotherapy sensitivity in SOC. By modulating key metabolic pathways and potentially suppressing WNT signaling, STAR + cells could contribute to improved treatment responses. These findings position STAR + cells as a promising biomarker for predicting chemotherapy efficacy in SOC, which warrants further investigation.


  • Open Access

    Conversion therapy with chemoimmunotherapy induced pCR in a stage IV lung squamous cell carcinoma patient harboring EGFR exon 20 insertion

    by Mingjin Xu, Xingfa Huo, Chuantao Zhang, Xuchen Zhang, Huiyun Wang, Hongmin Yang, Nan Ge, Yongjie Wang, Helei Hou

    This case study details an innovative conversion therapy strategy in a 58-year-old Asian male with baseline stage cT4N1M1b advanced lung squamous cell carcinoma (SCC) harboring a rare EGFR exon 20 insertion mutation with concurrent high PD-L1 expression who achieved a pathologic complete response (pCR) after preoperative immunotherapy plus chemotherapy. The patient initially presented with coughing and bloody sputum and was comprehensively diagnosed via PET/CT scanning, bronchoscopic biopsy and next-generation sequencing. After four cycles of platinum‒paclitaxel chemotherapy plus immunotherapy with pembrolizumab (a PD-1 blockade), significant primary tumor shrinkage and the disappearance of oligometastasis in the right adrenal gland were discovered via CT scans. The subsequent salvage lung surgery resulted in a pCR, and the patient continued postoperative maintenance immunotherapy. No evidence of disease relapse or immune-related adverse events occurred after a post-surgery follow-up time of 9.4 months. This case highlights the potential value and challenges of immunotherapy plus chemotherapy as conversion therapy strategy in treating patients with non-small cell lung cancer (NSCLC) harboring rare EGFR exon 20 insertions.

  • CD8 + T-Cell-Related Genes: Deciphering Their Role in the Pancreatic Adenocarcinoma TME and Their Effect on Prognosis

    by Yuming Zhang, Helei Hou, Xuchen Zhang, Hongwei Lan, Xingfa Huo, Xueqin Duan, Yufeng Li, Xiaochun Zhang, Na Zhou

    Background Because of the unique tumor microenvironment (TME), immunotherapy and targeted therapies have shown limited efficacy in treating pancreatic adenocarcinoma (PAAD). CD8 + T cells play crucial roles in regulating the TME in PAAD; therefore, exploring the function of CD8 + T-cell-related genes (CD8RGs) in PAAD has high potential clinical value and could provide a comprehensive understanding of the microenvironment of PAAD. Methods We employed the weighted gene coexpression network analysis and CIBERSORT algorithms to assess PAAD transcriptome data from The Cancer Genome Atlas (TCGA) dataset and identify modules strongly associated with CD8 + T cell infiltration. Using least absolute shrinkage and selection operator regression analysis and Kaplan–Meier curves, we developed a prognostic risk score model for patients with PAAD. We validated this model using single-cell and transcriptome datasets obtained from the Gene Expression Omnibus (GEO). We also examined the correlations between the risk score and factors such as the TME, clinical characteristics, and tumor mutation burden (TMB). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis were performed on differentially expressed genes between the high- and low-risk groups. In addition, the Tumor Immune Dysfunction and Exclusion website and “pRRophetic” R package were used to predict response to immunotherapy and chemotherapy in the high- and low-risk groups, respectively. Finally, we analyzed the expressions of hub genes at the cellular level with quantitative real-time PCR. Results A risk model based on five CD8RGs was established and validated using TCGA and GEO datasets. The low-risk group exhibited significantly longer overall and progression-free survival. A positive correlation between the TMB and the risk score was observed. The TME analysis revealed a significant correlation between the risk score and immune function, as well as immune checkpoints. The expression of hub genes was significantly correlated with the infiltration level of CD8 + T cells. The high-risk group responded better to immunotherapy, paclitaxel, cisplatin, mitomycin C, afatinib (BIBW2992), and gefitinib. In contrast, the low-risk group showed higher sensitivity to sunitinib, MK.2206, palbociclib (PD.0332991), and axitinib. Compared with that in normal pancreatic epithelial cells, the expression levels of BCL11A, PHOSPHO1, and GNG7 were significantly decreased, while those of KLK11 and VCAM1 were significantly increased in pancreatic tumor cells. Conclusions CD8RGs play an important role in regulating the TME of PAAD. Five hub genes—BCL11A, KLK11, GNG7, PHOSPHO1, and VCAM1—are closely associated with the prognosis of PAAD patients, providing new references for the exploration of biomarkers. Furthermore, our findings offer novel insights for clinical decision-making.

  • Open Access

    Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IVA gastric cancer patients: a single-center retrospective study

    by Xuchen Zhang, Huiyun Wang, Yi Li, Weihua Yan, Yunqing Chen, Shanai Song, Ning Liu, Chuantao Zhang, Zhaojian Niu, Helei Hou

    Currently, PD-(L)1 blockade-based neoadjuvant treatment has shown promising outcomes in patients with potentially resectable gastric cancer. In this real-world study, we aimed to retrospectively observe the efficacy including tumor response and event-free survival (EFS), and safety of PD-(L)1 blockade-based neoadjuvant treatment versus chemotherapy alone in potentially resectable gastric cancer patients with microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) status. We retrospectively collected the clinical data of patients with potentially resectable gastric cancer and MSI-H/dMMR status who received neoadjuvant treatment followed by D2 gastrectomy at the Affiliated Hospital of Qingdao University from January 2019 to June 2023. The outcomes of interest mainly included overall complete response (CR) rates, radiographical and pathological tumor response, treatment-related adverse events (TRAEs), and EFS. In total, 30 patients were included in the analysis; 23 patients received neoadjuvant PD-(L)1 blockade plus chemotherapy or PD-(L)1 blockade monotherapy, and seven patients received neoadjuvant chemotherapy. In the PD-(L)1 blockade-based treatment group, 7 of 23 patients (30.4%, 95% CI 0.141–0.530) achieved pathological CR (pCR), while three patients with radiographical CR did not undergo surgery. In contrast, 1 of 7 (14.3%) patients in the neoadjuvant chemotherapy group achieved pCR. The overall CR rate was 43.5% (10 of 23, 95% CI 0.239–0.651) in the PD-(L)1 blockade-based treatment group and 14.3% (1 of 7, 95% CI 0.026–0.513) in the chemotherapy group. The neoadjuvant PD-(L)1 blockade-based treatment regimen was mild and well tolerated. By the latest follow-up, median EFS time was not reached in both cohorts. In potentially resectable gastric cancer patients with MSI-H/dMMR status, PD-(L)1 blockade-based neoadjuvant treatment regimen provided promising clinical benefits and was well tolerated.


  • Open Access

    SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response

    by Yuming Zhang, Dantong Sun, Weizhong Han, Zhen Yang, Yongzhi Lu, Xuchen Zhang, Yongjie Wang, Chuantao Zhang, Ning Liu, Helei Hou

    The switch/sucrose non‐fermenting (SWI/SNF) complex family includes important chromatin‐remodeling factors that are frequently mutated in lung adenocarcinoma (LUAD). However, the role of one family member, SMARCA4, in LUAD prognosis and immunotherapy sensitivity remains unclear. In the present study, 6745 LUAD samples from the cBioPortal database were used to analyze the relationships between SMARCA4 mutations and patient prognoses and clinical characteristics. Additionally, we examined the correlation between SMARCA4 mutations and prognosis in patients treated with immunotherapy using two immune‐related datasets. SMARCA4 mutations and low expression were associated with shorter survival, and mutations were associated with a high tumor mutational burden and high microsatellite instability. SMARCA4 mutations were accompanied by KRAS, KEAP1, TP53 and STK11 mutations. No significant difference was observed in the immunotherapy response between patients with and without SMARCA4 mutations. When KRAS or STK11 mutations were present, immunotherapy effectiveness was poorer; however, when both SMARCA4 and TP53 mutations were present, immunotherapy was more effective. Furthermore, low SMARCA4 expression predicted a higher immunophenoscore, and SMARCA4 expression was correlated with certain immune microenvironment features. Taken together, our results suggest that SMARCA4 mutations and low expression might be associated with poor LUAD prognosis. Additionally, immunotherapy efficacy in patients with SMARCA4 mutations depended on the co‐mutant genes. Thus, SMARCA4 could be an important factor to be considered for LUAD diagnosis and treatment.